Xeris Pharmaceuticals Inc. (XERS) Reports In-Line Q2 EPS ; Offers Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $45.84 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $190-200 million, versus the consensus of $187.3 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Jefferies Starts FedEx Freight Holding Company (FDXF) at Buy
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform